Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis
Abstract Background Rapid progressive interstitial lung disease (RP-ILD) is the leading cause of anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis (anti-MDA5+DM) related death. Elevated serum B-cell activating factor (BAFF) levels have been implicated in connective...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-04-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-024-03153-6 |
| _version_ | 1827276943546908672 |
|---|---|
| author | Yumeng Shi Hanxiao You Chang Liu Yulu Qiu Chengyin Lv Yujing Zhu Lingxiao Xu Fang Wang Miaojia Zhang Wenfeng Tan |
| author_facet | Yumeng Shi Hanxiao You Chang Liu Yulu Qiu Chengyin Lv Yujing Zhu Lingxiao Xu Fang Wang Miaojia Zhang Wenfeng Tan |
| author_sort | Yumeng Shi |
| collection | DOAJ |
| description | Abstract Background Rapid progressive interstitial lung disease (RP-ILD) is the leading cause of anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis (anti-MDA5+DM) related death. Elevated serum B-cell activating factor (BAFF) levels have been implicated in connective tissue diseases associated ILD. Here, we evaluate whether BAFF could be a prognostic biomarker for predicting RP-ILD in anti-MDA5+DM patients. Methods Serums were collected from 39 patients with anti-MDA5+DM (20 with RP-ILD and 19 with non-RP-ILD), 20 antisynthase syndrome (ASS) patients and 20 healthy controls (HC). BAFF concentration was measured by an enzyme-linked immunosorbent assay. Results Serum BAFF level was higher in anti-MDA5+DM patients than those in ASS patients and HC (3882.32 ± 1880.09 vs. 2540.89 ± 1403.04 and 2486.28 ± 767.97 pg/mL, p = 0.0056 and 0.0038, respectively). Within anti-MDA5+DM groups, RP-ILD patients exhibited higher BAFF concentration than non-RP-ILD group (4549.78 ± 1839.97 vs. 3297.28 ± 1794.69 pg/mL, p = 0.04). The BAFF concentration was positively correlated with levels of C-reactive protein (CRP), dehydrogenase (LDH) and cytokeratin (CK) in anti-MDA5+DM patients (r = 0.350, p = 0.035; r = 0.393, p = 0.016; r = 0.518, p = 0.001; respectively). The best cut-off value of BAFF concentration was 2971.5 pg/mL by ROC curve (AUC area = 0.690, p = 0.045) and BAFF > 2971.5 pg/mL was an independent risk factor for RP-ILD using multivariate analysis (OR = 9.389, 95% CI = 1.609—54.769; p = 0.013). Conclusions Serum BAFF could be a useful prognostic biomarker for early detecting RP-ILD risk in anti-MDA5+DM patients. |
| first_indexed | 2024-04-24T07:11:26Z |
| format | Article |
| id | doaj.art-0541ae36b6d3406588e34c84d5d7e52d |
| institution | Directory Open Access Journal |
| issn | 1750-1172 |
| language | English |
| last_indexed | 2024-04-24T07:11:26Z |
| publishDate | 2024-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj.art-0541ae36b6d3406588e34c84d5d7e52d2024-04-21T11:30:19ZengBMCOrphanet Journal of Rare Diseases1750-11722024-04-011911910.1186/s13023-024-03153-6Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositisYumeng Shi0Hanxiao You1Chang Liu2Yulu Qiu3Chengyin Lv4Yujing Zhu5Lingxiao Xu6Fang Wang7Miaojia Zhang8Wenfeng Tan9Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical UniversityAbstract Background Rapid progressive interstitial lung disease (RP-ILD) is the leading cause of anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis (anti-MDA5+DM) related death. Elevated serum B-cell activating factor (BAFF) levels have been implicated in connective tissue diseases associated ILD. Here, we evaluate whether BAFF could be a prognostic biomarker for predicting RP-ILD in anti-MDA5+DM patients. Methods Serums were collected from 39 patients with anti-MDA5+DM (20 with RP-ILD and 19 with non-RP-ILD), 20 antisynthase syndrome (ASS) patients and 20 healthy controls (HC). BAFF concentration was measured by an enzyme-linked immunosorbent assay. Results Serum BAFF level was higher in anti-MDA5+DM patients than those in ASS patients and HC (3882.32 ± 1880.09 vs. 2540.89 ± 1403.04 and 2486.28 ± 767.97 pg/mL, p = 0.0056 and 0.0038, respectively). Within anti-MDA5+DM groups, RP-ILD patients exhibited higher BAFF concentration than non-RP-ILD group (4549.78 ± 1839.97 vs. 3297.28 ± 1794.69 pg/mL, p = 0.04). The BAFF concentration was positively correlated with levels of C-reactive protein (CRP), dehydrogenase (LDH) and cytokeratin (CK) in anti-MDA5+DM patients (r = 0.350, p = 0.035; r = 0.393, p = 0.016; r = 0.518, p = 0.001; respectively). The best cut-off value of BAFF concentration was 2971.5 pg/mL by ROC curve (AUC area = 0.690, p = 0.045) and BAFF > 2971.5 pg/mL was an independent risk factor for RP-ILD using multivariate analysis (OR = 9.389, 95% CI = 1.609—54.769; p = 0.013). Conclusions Serum BAFF could be a useful prognostic biomarker for early detecting RP-ILD risk in anti-MDA5+DM patients.https://doi.org/10.1186/s13023-024-03153-6BiomarkerDermatomyositisMelanoma differentiation-associated protein 5 antibodyRapidly progressive interstitial lung diseaseSerum B cell activating factor |
| spellingShingle | Yumeng Shi Hanxiao You Chang Liu Yulu Qiu Chengyin Lv Yujing Zhu Lingxiao Xu Fang Wang Miaojia Zhang Wenfeng Tan Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis Orphanet Journal of Rare Diseases Biomarker Dermatomyositis Melanoma differentiation-associated protein 5 antibody Rapidly progressive interstitial lung disease Serum B cell activating factor |
| title | Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis |
| title_full | Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis |
| title_fullStr | Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis |
| title_full_unstemmed | Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis |
| title_short | Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis |
| title_sort | elevated serum b cell activator factor levels predict rapid progressive interstitial lung disease in anti melanoma differentiation associated protein 5 antibody positive dermatomyositis |
| topic | Biomarker Dermatomyositis Melanoma differentiation-associated protein 5 antibody Rapidly progressive interstitial lung disease Serum B cell activating factor |
| url | https://doi.org/10.1186/s13023-024-03153-6 |
| work_keys_str_mv | AT yumengshi elevatedserumbcellactivatorfactorlevelspredictrapidprogressiveinterstitiallungdiseaseinantimelanomadifferentiationassociatedprotein5antibodypositivedermatomyositis AT hanxiaoyou elevatedserumbcellactivatorfactorlevelspredictrapidprogressiveinterstitiallungdiseaseinantimelanomadifferentiationassociatedprotein5antibodypositivedermatomyositis AT changliu elevatedserumbcellactivatorfactorlevelspredictrapidprogressiveinterstitiallungdiseaseinantimelanomadifferentiationassociatedprotein5antibodypositivedermatomyositis AT yuluqiu elevatedserumbcellactivatorfactorlevelspredictrapidprogressiveinterstitiallungdiseaseinantimelanomadifferentiationassociatedprotein5antibodypositivedermatomyositis AT chengyinlv elevatedserumbcellactivatorfactorlevelspredictrapidprogressiveinterstitiallungdiseaseinantimelanomadifferentiationassociatedprotein5antibodypositivedermatomyositis AT yujingzhu elevatedserumbcellactivatorfactorlevelspredictrapidprogressiveinterstitiallungdiseaseinantimelanomadifferentiationassociatedprotein5antibodypositivedermatomyositis AT lingxiaoxu elevatedserumbcellactivatorfactorlevelspredictrapidprogressiveinterstitiallungdiseaseinantimelanomadifferentiationassociatedprotein5antibodypositivedermatomyositis AT fangwang elevatedserumbcellactivatorfactorlevelspredictrapidprogressiveinterstitiallungdiseaseinantimelanomadifferentiationassociatedprotein5antibodypositivedermatomyositis AT miaojiazhang elevatedserumbcellactivatorfactorlevelspredictrapidprogressiveinterstitiallungdiseaseinantimelanomadifferentiationassociatedprotein5antibodypositivedermatomyositis AT wenfengtan elevatedserumbcellactivatorfactorlevelspredictrapidprogressiveinterstitiallungdiseaseinantimelanomadifferentiationassociatedprotein5antibodypositivedermatomyositis |